Quintiles chief: CROs need to jump on sequencing bandwagon

As genomics are playing an increasing role in drug development, CROs need to expand their capabilities to stay relevant, Quintiles CEO Tom Pike said. "Genetic sequencing is going to become more a part of clinical trials," Pike told Triangle Business Journal. "We're working closely to integrate (it) into our lab business and our clinical trial business." Naturally, Pike was mum on the swelling rumors that Quintiles is plotting an IPO, but he did say the company will pursue a few acquisitions in the future but focus on organic growth. Report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.